ZAMICASTAT ( DrugBank: Zamicastat )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 12 |
86. Pulmonary arterial hypertension
Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
Showing 1 to 10 of 12 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-002796-18-IT (EUCTR) | 28/11/2019 | 29/01/2021 | To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-51058-201, in the treatment of long-term PAH. To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-5105 ... | An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease - Safety and efficacy of BIA 5-1058 in PAH An open-label, multicentre study to evaluate the safety and efficacy of zamicastatas adjunctive ther ... | Pulmonary arterial hypertension MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary arterial hypertension MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: R ... | Product Name: zamicastat Product Code: [BIA-5-1058] INN or Proposed INN: zamicastat | BIAL-Portela & Ca, S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | Portugal;Spain;Ukraine;Austria;Germany;United Kingdom;Italy | ||
| 2 | EUCTR2018-002448-10-DE (EUCTR) | 08/11/2019 | 17/08/2018 | Study to find the most promising therapeutic dosage of zamicastat for the treatment of PAH disease. | An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH) - Pharmacokinetics, safety and efficacy of BIA 5-1058 in PAH An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastatas a ... | Pulmonary arterial hypertension;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: Zamicastat Product Code: BIA 5-1058 INN or Proposed INN: ZAMICASTAT Other descriptive name: BIA 5-1058 Product Name: Zamicastat Product Code: BIA 5-1058 INN or Proposed INN: ZAMICASTAT Other descriptive nam ... | Bial - Portela & Ca, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | Portugal;France;Spain;Belgium;Ukraine;Austria;Germany;United Kingdom;Italy | ||
| 3 | EUCTR2018-002448-10-IT (EUCTR) | 29/10/2019 | 01/02/2021 | Study to find the most promising therapeutic dosage of zamicastat for the treatment of PAH disease. | An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH) - Pharmacokinetics, safety and efficacy of BIA 5-1058 in PAH An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastatas a ... | Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pu ... | Product Name: zamicastat Product Code: [BIA 5-1058] INN or Proposed INN: zamicastat | BIAL-Portela & Ca, S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | Portugal;Spain;Ukraine;Austria;Germany;United Kingdom;Italy | ||
| 4 | EUCTR2018-002796-18-PT (EUCTR) | 30/07/2019 | 30/10/2018 | To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-51058-201, in the treatment of long-term PAH. To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-5105 ... | An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease An open-label, multicentre study to evaluate the safety and efficacy of zamicastatas adjunctive ther ... | Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pu ... | Product Name: Zamicastat Product Code: BIA-5-1058 INN or Proposed INN: ZAMICASTAT Other descriptive name: BIA 5-1058 Product Name: Zamicastat Product Code: BIA-5-1058 INN or Proposed INN: ZAMICASTAT Other descriptive nam ... | Bial - Portela & Ca, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | Portugal;Spain;Belgium;Ukraine;Austria;Germany;United Kingdom;Italy | ||
| 5 | NCT04316143 (ClinicalTrials.gov) | June 6, 2019 | 18/3/2020 | Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH | An Open-label, Multicentre Study to Evaluate Pharmacokinetics, Safety and Efficacy of Zamicastat as Adjunctive Therapy in Pulmonary Arterial Hypertension (PAH) An Open-label, Multicentre Study to Evaluate Pharmacokinetics, Safety and Efficacy of Zamicastatas A ... | Pulmonary Arterial Hypertension | Drug: Zamicastat | Bial - Portela C S.A. | NULL | Completed | 18 Years | 65 Years | All | 33 | Phase 2 | Spain |
| 6 | EUCTR2018-002796-18-GB (EUCTR) | 12/03/2019 | 19/06/2019 | To study the safety and how effective Long-term Zamicastat treatment is for Pulmonary Arterial Hypertension To study the safety and how effective Long-term Zamicastattreatment is for Pulmonary Arterial Hypert ... | An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease. - Safety and efficacy of BIA 5-1058 in PAH An open-label, multicentre study to evaluate the safety and efficacy of zamicastatas adjunctive ther ... | Pulmonary Arterial Hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary Arterial Hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pu ... | Product Name: Zamicastat Product Code: BIA 5-1058 INN or Proposed INN: Zamicastat | Bial - Portela & Ca, S.A | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 32 | Phase 2 | Portugal;Belgium;Spain;Ukraine;Austria;Netherlands;Germany;United Kingdom | ||
| 7 | EUCTR2018-002448-10-GB (EUCTR) | 11/02/2019 | 19/06/2019 | Multi centre study to assess the safety, effective and movement of Zamicastat within the body when given to a patient with pulmonary arterial hypertension as an additional medication. Multi centre study to assess the safety, effective and movement of Zamicastatwithin the body when gi ... | An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH) - Pharmcokinetics, safety and efficacy of BIA-5-1058 in PAH An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastatas a ... | Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pu ... | Product Name: Zamicastat Product Code: BIA 5-1058 | Bial - Portela & Ca, S.A | NULL | Not Recruiting | Female: yes Male: yes | 32 | Phase 2 | Portugal;Spain;Ukraine;Austria;Netherlands;Germany;United Kingdom | ||
| 8 | EUCTR2018-002796-18-ES (EUCTR) | 17/01/2019 | 16/11/2018 | To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-51058-201, in the treatment of long-term PAH. To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-5105 ... | An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease An open-label, multicentre study to evaluate the safety and efficacy of zamicastatas adjunctive ther ... | Pulmonary arterial hypertension MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary arterial hypertension MedDRA version: 20.0;Level: PT;Classification code 10064911;Term: Pu ... | Product Name: Zamicastat Product Code: BIA-5-1058 INN or Proposed INN: ZAMICASTAT Other descriptive name: BIA 5-1058 Product Name: Zamicastat Product Code: BIA-5-1058 INN or Proposed INN: ZAMICASTAT Other descriptive nam ... | Bial - Portela & Ca, S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ... | Portugal;Spain;Ukraine;Austria;United Kingdom | ||
| 9 | EUCTR2018-002796-18-AT (EUCTR) | 20/12/2018 | 06/11/2018 | To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-51058-201, in the treatment of long-term PAH. To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-5105 ... | An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease An open-label, multicentre study to evaluate the safety and efficacy of zamicastatas adjunctive ther ... | Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pu ... | Product Name: Zamicastat Product Code: BIA-5-1058 INN or Proposed INN: ZAMICASTAT Other descriptive name: BIA 5-1058 Product Name: Zamicastat Product Code: BIA-5-1058 INN or Proposed INN: ZAMICASTAT Other descriptive nam ... | Bial - Portela & Ca, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | Portugal;Spain;Ukraine;Austria;Germany;United Kingdom;Italy | ||
| 10 | EUCTR2018-002448-10-PT (EUCTR) | 26/11/2018 | 04/09/2018 | Study to find the most promising therapeutic dosage of zamicastat for the treatment of PAH disease. | An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH) - Pharmacokinetics, safety and efficacy of BIA 5-1058 in PAH An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastatas a ... | Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pu ... | Product Name: Zamicastat Product Code: BIA 5-1058 INN or Proposed INN: ZAMICASTAT Other descriptive name: BIA 5-1058 Product Name: Zamicastat Product Code: BIA 5-1058 INN or Proposed INN: ZAMICASTAT Other descriptive nam ... | Bial - Portela & Ca, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;Portugal;Spain;Belgium;Ukraine;Austria;Netherlands;Germany;United Kingdom;Italy |